Literature DB >> 24516020

Brivanib for hepatocellular carcinoma trials: selection bias from barcelona clinic liver cancer stage?

Xingshun Qi1, Jia Jia, Daiming Fan, Guohong Han.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24516020     DOI: 10.1200/JCO.2013.53.8199

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  2 in total

1.  Expression of Ovol2 is related to epithelial characteristics and shows a favorable clinical outcome in hepatocellular carcinoma.

Authors:  Hui Fu; Lisha Qi; Lu Chen; Yuchao He; Ning Zhang; Hua Guo
Journal:  Onco Targets Ther       Date:  2016-09-29       Impact factor: 4.147

2.  Downregulation of Epstein-Barr virus-induced gene 3 is associated with poor prognosis of hepatocellular carcinoma after curative resection.

Authors:  Qingjie Song; Xi Chen; Weidong Hu; Guanglin Mei; Xiaobing Yang; Han Wu
Journal:  Oncol Lett       Date:  2018-03-15       Impact factor: 2.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.